Table 1 Patient characteristics, labs and vital parameters expressed as median (interquartile range [IQR]) or no (percentage (%))
| Unmatched groups | Matched groups | |||||||
|---|---|---|---|---|---|---|---|---|
|
Controls n = 615 |
VK group n = 134 | Standardized difference | p value |
Controls n = 129 |
VK group n = 129 | Standardized difference | p value | |
| Variables included in matching | ||||||||
| SAPS 3 EMR | 24 (10–45) | 26 (14–45) (20.8) | 0.033 | 0.38 | 28 (12–47) | 26 (14–42) | − 0.088 | 0.64 |
| Age (years) | 67 (54–75) | 68 (55–75) | − 0.004 | 0.99 | 68 (54–75) | 67 (55–74) | − 0.041 | 0.62 |
| Pre-treatment PT-INR | 1.3 (1.3–1.4) | 1.5 (1.4–1.6) | 0.78 | < 0.001 | 1.5 (1.4–1.6) | 1.5 (1.4–1.6) | 0.005 | 0.96 |
| Sex (female) | 204 (33) | 43 (30) | − 0.023 | 0.81 | 43 (33) | 42 (33) | − 0.017 | 0.90 |
| Baseline variables not included in matching | ||||||||
| Reasons for admissiona, n (%) | ||||||||
| Severe sepsis or septic shockb | 159 (26) | 53 (40) | NA | 0.001 | 53 (41) | 52 (40) | NA | 0.90 |
| Trauma | 61 (10) | 16 (12) | NA | 0.49 | 4 (3) | 15 (12) | NA | 0.009 |
| CNS | 254 (41) | 33 (25) | NA | < 0.001 | 32 (25) | 31 (24) | NA | 0.89 |
| Haematologic | 41 (7) | 9 (7) | NA | 0.99 | 8 (6) | 8 (6) | NA | 1.0 |
| Gastric | 103 (17) | 38 (28) | NA | 0.002 | 31 (24) | 38 (29) | NA | 0.33 |
| Metabolic | 100 (16) | 17 (13) | NA | 0.30 | 23 (18) | 17 (13) | NA | 0.30 |
| Respiratory | 301 (49) | 72 (54) | NA | 0.32 | 69 (53) | 69 (53) | NA | 1.0 |
| Cardiovascular | 226 (37) | 28 (21) | NA | < 0.001 | 51 (40) | 27 (21) | NA | 0.001 |
| Hepatic | 30 (5) | 9 (7) | NA | 0.39 | 7 (5) | 9 (7) | NA | 0.61 |
| Renal | 130 (21) | 27 (20) | NA | 0.79 | 38 (29) | 27 (21) | NA | 0.12 |
| Other | 50 (8) | 15 (11) | NA | 0.26 | 12 (9) | 14 (11) | NA | 0.68 |
| Comorbidities, n (%)c | ||||||||
| Cancerd | 85 (14) | 26 (19) | NA | 0.099 | 15 (12) | 23 (18) | NA | 0.15 |
| Congestive heart failuree | 30 (5) | 9 (7) | NA | 0.39 | 10 (8) | 8 (6) | NA | 0.63 |
| Haematological malignancyf | 22 (4) | 6 (4) | NA | 0.62 | 10 (8) | 6 (5) | NA | 0.31 |
| Immunosuppressive therapyg | 35 (6) | 6 (4) | NA | 0.58 | 8 (6) | 6 (5) | NA | 0.59 |
| Multiple comorbidities | 13 (2) | 3 (2) | NA | 0.93 | 2 (2) | 3 (2) | NA | 0.65 |